Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taisho Buys Biofermin In All-Japanese Acquisition

This article was originally published in PharmAsia News

Executive Summary

Japan's Taisho Pharmaceutical has bought a controlling interest in Biofermin Pharmaceutical for $240.2 million. The Taisho purchase amounts to a 54.8 percent stake in Biofermin, which Taisho plans to make a subsidiary. Biofermin has a marketing agreement with Takeda Pharmaceutical, which opposed the Taisho bid, but that contract is to remain in place. The acquiring company plans to develop lactobacillus products, using Biofermin facilities. (Click here for more - may require a subscription



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts